Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 3421 AL 3435

Acetylcholinesterase inhibitors combined with memantine for moderate to severe Alzheimer's disease: a meta-analysis

Glinz D, Gloy VL, Monsch AU, Kressig RW, Patel C, McCord KA, Ademi Z, Tomonaga Y, Schwenkglenks M, Bucher HC, Raatz H.

Swiss Med Wkly. 2019 Jun 30;149:w20093. doi: 10.4414/smw.2019.20093. eCollection 2019 Jun 17.

Current and emerging avenues for Alzheimer's disease drug targets

Loera-Valencia R, Cedazo-Minguez A, Kenigsberg PA, Page G, Duarte AI, Giusti P, Zusso M, Robert P, Frisoni GB, Cattaneo A, Zille M, Boltze J, Cartier N, Buee L, Johansson G, Winblad B.

J Intern Med. 2019 Oct;286(4):398-437. doi: 10.1111/joim.12959. Epub 2019 Aug 29.

Human glutaminyl cyclase: Structure, function, inhibitors and involvement in Alzheimer's disease

Vijayan DK, Zhang KYJ.

Pharmacol Res. 2019 Sep;147:104342. doi: 10.1016/j.phrs.2019.104342. Epub 2019 Jul 6.

Are some animal models more equal than others? A case study on the translational value of animal models of efficacy for Alzheimer's disease

Veening-Griffioen DH, Ferreira GS, van Meer PJK, Boon WPC, Gispen-de Wied CC, Moors EHM, Schellekens H.

Eur J Pharmacol. 2019 Sep 15;859:172524. doi: 10.1016/j.ejphar.2019.172524. Epub 2019 Jul 7.

Cu(II) Binding Properties of N-Truncated Aβ Peptides: In Search of Biological Function

Stefaniak E, Bal W.

Inorg Chem. 2019 Oct 21;58(20):13561-13577. doi: 10.1021/acs.inorgchem.9b01399. Epub 2019 Jul 15.

Advancements in nanotherapeutics for Alzheimer's disease: current perspectives

Harilal S, Jose J, Parambi DGT, Kumar R, Mathew GE, Uddin MS, Kim H, Mathew B.

J Pharm Pharmacol. 2019 Sep;71(9):1370-1383. doi: 10.1111/jphp.13132. Epub 2019 Jul 15.

Allosteric Modulators of Potential Targets Related to Alzheimer's Disease: a Review

Silva GM, Barcelos MP, Poiani JGC, Hage-Melim LIDS, da Silva CHTP.

ChemMedChem. 2019 Aug 20;14(16):1467-1483. doi: 10.1002/cmdc.201900299. Epub 2019 Aug 1.

Beneficial Effects of Fingolimod in Alzheimer's Disease: Molecular Mechanisms and Therapeutic Potential

Angelopoulou E, Piperi C.

Neuromolecular Med. 2019 Sep;21(3):227-238. doi: 10.1007/s12017-019-08558-2. Epub 2019 Jul 16.

Advance of sporadic Alzheimer's disease animal models

Zhang L, Chen C, Mak MS, Lu J, Wu Z, Chen Q, Han Y, Li Y, Pi R.

Med Res Rev. 2020 Jan;40(1):431-458. doi: 10.1002/med.21624. Epub 2019 Jul 22.

Diabetes drugs in the fight against Alzheimer's disease

Boccardi V, Murasecco I, Mecocci P.

Ageing Res Rev. 2019 Sep;54:100936. doi: 10.1016/j.arr.2019.100936. Epub 2019 Jul 19.

Anti-Aβ Antibodies and Cerebral Amyloid Angiopathy Complications

Chantran Y, Capron J, Alamowitch S, Aucouturier P.

Front Immunol. 2019 Jul 4;10:1534. doi: 10.3389/fimmu.2019.01534. eCollection 2019.

Targeting apolipoprotein E for treating Alzheimer's disease

Bales KR, Paul SM.

Neurosci Lett. 2019 Sep 14;709:134366. doi: 10.1016/j.neulet.2019.134366. Epub 2019 Jul 20.

BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease

Moussa-Pacha NM, Abdin SM, Omar HA, Alniss H, Al-Tel TH.

Med Res Rev. 2020 Jan;40(1):339-384. doi: 10.1002/med.21622. Epub 2019 Jul 26.

The effects of insulin and insulin-like growth factor I on amyloid precursor protein phosphorylation in in vitro and in vivo models of Alzheimer's disease

Kim B, Elzinga SE, Henn RE, McGinley LM, Feldman EL.

Neurobiol Dis. 2019 Dec;132:104541. doi: 10.1016/j.nbd.2019.104541. Epub 2019 Jul 23.

Triazole derivatives as inhibitors of Alzheimer's disease: Current developments and structure-activity relationships

Xu M, Peng Y, Zhu L, Wang S, Ji J, Rakesh KP.

Eur J Med Chem. 2019 Oct 15;180:656-672. doi: 10.1016/j.ejmech.2019.07.059. Epub 2019 Jul 22.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias